The changing market is forcing the drugmakers to hire people with more consumer-focused expertise, strike more deals with ...

On average, Mochi Health members lose 36 pounds in their first year, and most sustain their weight loss much longer than they ...

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

U.S. President Donald Trump, Eli Lilly (LLY.N) and Novo Nordisk (NOVOb.CO) signed a deal in November to slash the prices of ...

Some Medicare enrollees may soon be able to access super-popular drugs for obesity under a voluntary model program, the Centers for Medicare and Medicaid Services announced Tuesday. Eligible ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

This new pill contains the same active ingredient as injectable Wegovy and Ozempic, semaglutide. It is the first GLP-1 pill ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...